Constructor Capital, the venture arm of the Swiss-based Constructor Group ecosystem, has closed its inaugural fund at $110 million, marking a significant milestone for science-driven venture investing. The new fund positions Constructor Capital as a specialised backer of early-stage companies built on deep scientific and technical foundations, aiming to bridge the long-standing gap between academic research and commercial scale.
A Fund Built Around Science First Investing
Constructor Capital is designed to operate differently from traditional venture capital firms. Its investment strategy is rooted in a science-first approach that prioritises deep technical validation, academic insight, and long-term research impact alongside commercial potential. The firm draws on an extensive network of more than 50 universities and a broad community of academic researchers to inform sourcing, due diligence, and portfolio support.
This structure enables the fund to assess highly complex technologies that often sit outside the comfort zone of conventional investors. Many of these innovations originate in university labs or research institutions and require patient capital, specialised knowledge, and hands-on support to transition successfully into market-ready businesses.
Embedded in a Global Innovation Ecosystem
Constructor Capital operates within the wider Constructor Group, a global education and research ecosystem that includes Constructor University, research laboratories, an equity-free accelerator programme, and platforms focused on applied innovation. This embedded position allows Constructor Capital to integrate scientific expertise directly into its investment process rather than relying solely on external advisors.
By working closely with researchers, faculty, and technologists, the fund is able to support founders as they move from experimental environments into commercial execution. This includes assistance with product development, talent recruitment, operational scaling, and navigating the early challenges of company building.
Bridging the Gap From Lab to Market
According to Matthias Winter, Managing Partner at Constructor Capital, research institutions worldwide are producing technologies with the potential to reshape industries, yet many remain underfunded or overlooked by venture capital. He explained that the fund was created to help translate this scientific capital into scalable companies by combining academic depth with operational discipline.
The fund’s model aims to reduce the friction founders often face when commercialising advanced research, particularly in areas that require long development cycles, specialised infrastructure, or non-traditional go-to-market strategies.
Investment Focus and Global Reach
Constructor Capital focuses on seed and Series A investments across deeptech, software, and edtech. The fund plans to lead and co-lead rounds, with typical initial investments ranging from $1 million to $10 million and select investments of up to $15 million. Capital has also been reserved for follow-on funding to support portfolio companies as they grow.
The fund invests globally, with activity spanning Europe, the United States, the UAE, and Singapore. This international outlook reflects the increasingly global nature of scientific research and the need to support founders wherever breakthrough technologies emerge.
Early Portfolio Highlights
The fund has already built a portfolio of science-led companies operating at the forefront of advanced computing and systems. Investments include QuEra Computing, which is developing neutral-atom quantum computing systems, and Lumai, a company focused on 3D optical computing architectures designed to deliver more efficient AI inference.
Additional portfolio companies include AI infrastructure provider GCore, ERP platform Osome, and augmented reality innovator VitreaLab. Together, these investments reflect Constructor Capital’s emphasis on foundational technologies with long-term impact across multiple industries.
With its first fund now closed, Constructor Capital is positioning itself as a long-term partner for founders building the next generation of science-based companies, combining academic insight, operational support, and patient capital to help innovations move from the lab into the real economy.
